血液学の最新論文 | Hematopaseo

血液専門医と医療関係者のための情報サイト「ヘマトパセオ」

血液学の最新論文（2019年5月リリース分）New reports on Hematology

Leukemia

Lymphoma

Myeloma

Blood Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Blood. 2019 May 21. pii: blood.2019000722. doi: 10.1182/blood.2019000722. Chari A, Martinez-Lopez J, Mateos MV, Blad_ J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P
Blood Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. 133(18):1953-1963 Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J
Br J Haematol Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 May 24. doi: 10.1111/bjh.15969. Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA
Br J Haematol Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. Br J Haematol. 2019 May 22. doi: 10.1111/bjh.15972. Mlak R, Szudy-Szczyrek A, Mazurek M, Szczyrek M, Homa-Mlak I, Mielnik M, Chocholska S, Jankowska-__cka O, Ma_ecka-Massalska T, Hus M
Br J Haematol Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. Br J Haematol. 2019 May 15. doi: 10.1111/bjh.15946. Mateos MV, Orlowski RZ, Ocio EM, Rodríguez-Otero P, Reece D, Moreau P, Munshi N, Avigan DE, Siegel DS, Ghori R, Farooqui MZH, Marinello P, San-Miguel J
Br J Haematol Do we need cytogenetics in the follow-up of multiple myeloma? 185(3):399-401 Gay F, Goldschmidt H
Br J Haematol The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. 185(3):450-467 Cook G, Royle KL, O'Connor S, Cairns DA, Ashcroft AJ, Williams CD, Hockaday A, Cavenagh JD, Snowden JA, Ademokun D, Tholouli E, Andrews VE, Jenner M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Drayson MT, Brown JM, Morris TCM; National Cancer Research Institute Haemato-oncology Clinical Studies Group
Br J Haematol Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. 185(3):492-502 Yimer H, Melear J, Faber E, Bensinger WI, Burke JM, Narang M, Stevens D, Gunawardena S, Lutska Y, Qi K, Ukropec J, Qi M, Lin TS, Rifkin RM
Haematologica Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. Haematologica. 2019 May 23. pii: haematol.2018.213314. doi: 10.3324/haematol.2018.213314. Holthof LC, van der Horst HJ, van Hal-van Veen SE, Ruiter RWJ, Li F, Buijze M, Andersen MN, Yuan H, de Bruijn J, van de Donk NWCJ, Lokhorst HM, Zweegman S, Groen RWJ, Mutis T
Haematologica Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model. Haematologica. 2019 May 17. pii: haematol.2018.212266. doi: 10.3324/haematol.2018.212266. Natoni A, Farrell ML, Harris S, Falank C, Kirkham-McCarthy L, Macauley MS, Reagan MR, O' Dwyer M
Haematologica Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. 104(5):1026-1035 Blommestein HM, van Beurden-Tan CHY, Franken MG, Uyl-de Groot CA, Sonneveld P, Zweegman S
J Clin Oncol Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. J Clin Oncol. 2019 May 15:JCO1800776. doi: 10.1200/JCO.18.00776. Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Fontan J, Voillat L, Demarquette H, Collet P, Rodon P, Sohn C, Lifermann F, Orsini-Piocelle F, Richez V, Mohty M, Macro M, Minvielle S, Moreau P, Leleu X, Facon T, Attal M, Avet-Loiseau H, Corre J
J Clin Oncol Importance of Assessing Patient-Reported Outcomes With Salvage Autologous Transplantation in Relapsed Multiple Myeloma. J Clin Oncol. 2019 May 14:JCO1900865. doi: 10.1200/JCO.19.00865. Shaw BE, D'Souza A, Lee SJ
J Clin Oncol Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. 37(14):1228-1263 Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, Martin T
Lancet Haematol Improving the conditioning regimen in multiple myeloma. 6(5):e234-e235 Mateos MV, González-Calle V
Lancet Haematol Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. 6(5):e266-e275 Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH
Lancet Oncol Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019 May 13. pii: S1470-2045(19)30152-4. doi: 10.1016/S1470-2045(19)30152-4. Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators
Lancet Oncol Redefining the treatment paradigm for multiple myeloma. Lancet Oncol. 2019 May 13. pii: S1470-2045(19)30295-5. doi: 10.1016/S1470-2045(19)30295-5. Gay F, Mina R
Lancet Oncol CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet Oncol. 2019 May 10. pii: S1470-2045(19)30288-8. doi: 10.1016/S1470-2045(19)30288-8. Stirrups R
Lancet Oncol NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. 20(5):619-620 Elsada A, Adler AI
Leukemia Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling. Leukemia. 2019 May 29. doi: 10.1038/s41375-019-0493-x. Ho M, Chen T, Liu J, Dowling P, Hideshima T, Zhang L, Morelli E, Camci-Unal G, Wu X, Tai YT, Wen K, Samur M, Schlossman RL, Mazitschek R, Kavanagh EL, Lindsay S, Harada T, McCann A, Anderson KC, O'Gorman P, Bianchi G
Leukemia The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2019 May 15. doi: 10.1038/s41375-019-0482-0. Raab MS, Thomas SK, Ocio EM, Guenther A, Goh YT, Talpaz M, Hohmann N, Zhao S, Xiang F, Simon C, Vanasse KG, Kumar SK
Leukemia Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. 33(5):1063-1075 van Andel H, Kocemba KA, Spaargaren M, Pals ST
Leukemia Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. 33(5):1273-1277 Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis TV, Warsame R, Kyle RA, Kumar SK
Leukemia Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. 33(5):1291-1296 Matulis SM, Gupta VA, Neri P, Bahlis NJ, Maciag P, Leverson JD, Heffner LT Jr, Lonial S, Nooka AK, Kaufman JL, Boise LH
Leukemia Response to the Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma”. 33(5):1301-1302 Barosi G, Gale RP
N Engl J Med Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. 380(22):2104-2115 Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators; the MAIA Trial Investigators
N Engl J Med Initial Therapy in Older Patients with Multiple Myeloma. 380(22):2172-2173 Laubach J
N Engl J Med Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. 380(18):1726-1737 Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN

SCT

HSC

Anemia

Bone marrow failure

Haematologica Novel variants in Iranian individuals suspected to have inherited red blood cell disorders, including bone marrow failure syndromes. Haematologica. 2019 May 16. pii: haematol.2019.216069. doi: 10.3324/haematol.2019.216069. Neishabury M, Mehri M, Fattahi Z, Najmabadi H, Azarkeivan A

ITP